Headlines about Miragen Therapeutics (NASDAQ:MGEN) have trended somewhat positive on Wednesday, according to Accern. Accern identifies negative and positive news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Miragen Therapeutics earned a media sentiment score of 0.19 on Accern’s scale. Accern also assigned news headlines about the medical research company an impact score of 48.9739473210685 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
These are some of the headlines that may have effected Accern’s rankings:
Shares of MGEN traded up $0.01 on Wednesday, hitting $7.26. 1,000 shares of the stock traded hands, compared to its average volume of 147,353. The company has a market capitalization of $225.84 million, a P/E ratio of -5.26 and a beta of 1.32. The company has a quick ratio of 20.91, a current ratio of 20.91 and a debt-to-equity ratio of 0.14. Miragen Therapeutics has a one year low of $5.01 and a one year high of $15.91.
Miragen Therapeutics (NASDAQ:MGEN) last announced its quarterly earnings results on Wednesday, May 9th. The medical research company reported ($0.18) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.25) by $0.07. The company had revenue of $4.78 million during the quarter, compared to the consensus estimate of $1.17 million. Miragen Therapeutics had a negative net margin of 290.61% and a negative return on equity of 50.53%. sell-side analysts expect that Miragen Therapeutics will post -1.11 EPS for the current year.
A number of equities analysts have weighed in on MGEN shares. Zacks Investment Research downgraded shares of Miragen Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, January 25th. Deutsche Bank started coverage on shares of Miragen Therapeutics in a research note on Thursday, March 22nd. They set a “buy” rating and a $15.00 target price for the company. Evercore ISI started coverage on shares of Miragen Therapeutics in a research note on Friday, March 9th. They set an “outperform” rating and a $19.00 target price for the company. Wedbush reaffirmed an “outperform” rating on shares of Miragen Therapeutics in a research note on Tuesday, March 20th. Finally, Cann reaffirmed a “buy” rating and set a $13.00 target price on shares of Miragen Therapeutics in a research note on Friday, February 2nd. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and eight have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $16.11.
Miragen Therapeutics Company Profile
Miragen Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. Its three lead product candidates include cobomarsen, an inhibitor of microRNA-155, which is in Phase I clinical trial for treating cutaneous T-cell lymphoma; MRG-201, a replacement for microRNA-29, which is in Phase I clinical trial that is found at low levels in various pathological fibrotic conditions, including cutaneous, cardiac, renal, hepatic, and pulmonary fibrosis, as well as systemic sclerosis; and MRG-110, an inhibitor of microRNA-92 that is expressed in endothelial cells and has shown to accelerate the formation of new blood vessels in preclinical models of heart failure, peripheral ischemia, and dermal wounding in the United States and Japan.
Receive News & Ratings for Miragen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Miragen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.